тел. +38 (044) 483-12-82

№4(6) 2023

Укр

DOI 10.37219/2528-8253-2023-4-96

Zabolotna DD, Naumenko OM, Bobyr VV, Turova LO

ALLERGEN-SPECIFIC IMMUNOTHERAPY: CURRENT PERSPECTIVE

Zabolotna Diana D
State Institution “O.S. Kolomiychenko Institute of Otolaryngology of National Academy of Medical Science of Ukraine”; Kyiv, Ukraine.
Head of Department of Rhinology and Allergology with a group of radiology
Doctor of Medical Sciences, Professor
E-mail: dianazab@ukr.net
ORCID ID: https://orcid.org/0000-0001-7807-8148
Scopus Author ID: 57208163951

Naumenko Oleksandr
National medical University named after O.O. Bogomolets, Kyiv, Ukraine
First vice-rector, Doctor of Medical Sciences, Professor, Corresponding member of the National Academy of Science of Ukraine
E-mail: naumenko16t@ukr.net
ORCID ID: https://orcid.org/0000-0002-9001-7580
Scopus Author ID: 7005396556

Bobyr Vitaly V
Bogomolets National Medical University, Kyiv, Ukraine
Department of microbiology and parasitology with the basics of immunology
Doctor of Medical Sciences, Professor
ORCID ID: https://orcid.org/0000-0002-8310-8011
Scopus Author ID: 56274271500

Turova Lyudmila O
Bogomolets National Medical University, Kyiv, Ukraine
Department of Clinical Immunology and Allergology with Medical Genetics Section
PhD
ORCID ID: https://orcid.org/0000-0002-4481-3009
Scopus Author ID: 57031894300
ResearcherID: HTL-6869-2023

Abstract

Keywords: IgE-mediated diseases; allergens; allergen-specific immunotherapy; desensitization; regulatory T cells;

regulatory B cells; histamine receptors; mast cell

Keywords: IgE-mediated diseases; allergens; allergen-specific immunotherapy; desensitization; regulatory T cells;

regulatory B cells; histamine receptors; mast cell

This review is based on the ACIT theoretical aspects. The mechanisms of action, current approaches of using allergens and their dosage, safety and effectiveness of allergy treatment are described here. The ACIT current perspective indicates the gradual development and improvement of this method, due to the patient individual approaches and safety. In general, immunotherapy continues to evolve, and scientists continue to explore new methods and approaches to improve its effectiveness and use in the treatment of various diseases.

Keywords: allergen-specific immunotherapy, allergens, regulatory T-cells, immunological tolerance, biomarkers.

Download.PDF

References

  1. Ring J. Allergy in Practice. Berlin Heidelberg New York: Springer, 2005.
  2. Larché M, Cezmi A, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006 Oct;6(10):761-71.doi: 10.1038/nri1934.
  3. de Weck AL, Ring J. CIA, Collegium Internationale Allergologicum: History and Aims of a Special International Community Devoted to Allergy Research, 1954-1996, 2nd Munich: Urban Vogel, 2006.
  4. Schadewaldt H. Geschichte der Allergie, Band 1-4. 1st Muenchen-Deisenhofen: Dustri-Verlag, 1979, 1983.
  5. Stefan Riedel. Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent). 2005 Jan;18(1):21-25. doi: 1080/08998280.2005.11928028.
  6. Decker WK,  da Silva RF, Sanabria MH, Angelo SL, Guimarães F, Burt BM, al. Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models. Front Immunol. 2017;8:829. doi: 10.3389/fimmu.2017.00829.
  7. Zhang C. Hybridoma technology for the generation of monoclonal antibodies. Methods Mol Biol. 2012; 901:117-35. doi: 10.1007/978-1-61779-931-0_7.
  8. Bousquet J, Lockey R, Malling H. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol. 1998 Oct;102(4 Pt 1):558-62. doi: 10.1016/s0091-6749(98)70271-4.
  9. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International Consensus on Allergen Immunotherapy II: Mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016 Feb;137(2):358-68. doi: 10.1016/j.jaci.2015.12.1300.
  10. Creticos P, Esch R, Couroux P, Gentile D, D’Angelo P, Whitlow B, et al. Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2014 Mar;133(3):751-8. doi: 10.1016/j.jaci.2013.10.041.
  11. Passalacqua G, Canonica GW. Allergen immunotherapy: history and future developments. Immunol Allergy Clin North Am. 2016 Feb;36(1):1-12. doi: 10.1016/j.iac.2015.08.001.
  12. Wilson DR, Lima MT, Durham SR. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy. 2005 Jan;60(1):4-12.doi: 10.1111/j.1398-9995.2005.00699.x.
  13. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011 Jan;127(1):18-27; quiz 28-9. doi: 10.1016/j.jaci.2010.11.030.
  14. Holgate ST. Epithelial damage and response. Clin Exp Allergy. 2000 Jun:30 Suppl 1:37-41. doi: 10.1046/j.1365-2222.2000.00095.x.
  15. Lambrecht BN, Hammad H. The airway epithelium in asthma. Nat Med. 2012 May 4;18(5):684-92. doi: 10.1038/nm.2737.
  16. Lloyd CM, Hessel EM. Functions of T cells in asthma: more than just T(H)2 cells. Nat Rev Immunol. 2010 Dec;10(12):838-48. doi: 10.1038/nri2870.
  17. Barnes PJ. Targeting cytokines to treat asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2018 Jul;18(7):454-466. doi: 10.1038/s41577-018-0006-6.
  18. Pulendran B, Tang H, Manicassamy S. Programming dendritic cells to induce T(H)2 and tolerogenic responses. Nat Immunol. 2010 Aug;11(8): 647-55. doi: 10.1038/ni.1894.
  19. Suuring M, Moreau A. Regulatory macrophages and tolerogenic dendritic cells in myeloid regulatory cell-based therapies. Int J Mol Sci. 2021 Jul 26;22(15):7970. doi: 10.3390/ijms22157970.
  20. Castenmiller C, Keumatio-Doungtsop BC, van Ree R, de Jong EC, van Kooyk Y. Tolerogenic immunotherapy: targeting DC surface receptors to induce antigen-specific tolerance. Front Immunol. 2021 Feb 19:12:643240. doi: 10.3389/fimmu.2021.643240.
  21. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. 2003 May; 18(5):605-17. doi: 10.1016/s1074-7613(03)00113-4.
  22. Akbari O, DeKruyff RH, Umetsu DT. Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen. Nat Immunol. 2001 Aug;2(8):725-31. doi: 10.1038/90667.
  23. Medawar PB. Immunological tolerance. 1961 Jan 7:189:14-7. doi: 10.1038/189014a0.
  24. Soyer U, Akdis M, Ring J, Behrendt H, Crameri R, Lauener R, Akdis CA. Mechanisms of peripheral tolerance to allergens. Allergy. 2013 Feb;68(2): 161-70. doi: 10.1111/all.12085.
  25. Taams LS, Palmer DB, Akbar AN, Robinson DS, Brown Z, Hawrylowicz CM. Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology. 2006 May;118(1):1-9. doi: 10.1111/j.1365-2567.2006.02348.x.
  26. Larché Regulatory T Cells in Allergy and Asthma. Chest. 2007 Sep;132(3):1007-14. doi: 10.1378/chest.06-2434.
  27. Huang HJ, Curin M, Banerjee S, Chen KW, Garmatiuk T, Resch‐Marat Y, et al. A hypoallergenic peptide mix containing T cell epitopes of the clinically relevant house dust mite allergens. 2019 Dec;74(12):2461-2478. doi: 10.1111/all.13956.
  28. Benito-Villalvilla C, Pérez-Diego M, Angelina A, Kisand K, Rebane A, Subiza JL, et al. Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring. J Allergy Clin Immunol. 2022 Jan;149(1):212-222.e9. doi: 10.1016/j.jaci.2021.06.012.
  29. Scheiblhofer S, Thalhamer J, Weiss R. DNA and mRNA vaccination against allergies. Pediatr Allergy Immunol. 2018 Nov;29(7):679-688. doi: 10.1111/pai.12964.
  30. Zubeldia JM, Ferrer M, Dávila I, Justicia Adjuvants in Allergen-Specific Immunotherapy: Modulating and Enhancing the Immune Response. J Investig Allergol Clin Immunol. 2019;29(2):103-111. doi: 10.18176/jiaci.0349.
  31. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I,  et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011 Jan;127(1 Suppl):S1-55. doi: 10.1016/j.jaci.2010.09.034.
  32. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2006 Feb;117(2):319-25. doi: 10.1016/j.jaci.2005.11.014.
  33. Jutel M, Agache I, Bonini S, Burks AW, Calderon M, Canonica W, et al. International consensus on allergen immunotherapy II: mechanisms, standardization, and pharmacoeconomics. J Allergy Clin Immunol. 2016 Feb;137(2):358-68. doi: 10.1016/j.jaci.2015.12.1300.
  34. Dhami S, Nurmatov U, Arasi S, Khan T, Asaria M, Zaman H, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy. 2017 Nov;72(11): 1597-1631. doi: 10.1111/all.13201.
  35. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007 Jan 24;2007(1):CD001936. doi: 10.1002/14651858.CD001936.pub2.
  36. Nadeau KC, Schneider LC, Hoyte L, Borras I, Umetsu DT. Rapid oral desensitization in combination with omalizumab therapy in patients with cow’s milk allergy. J Allergy Clin Immunol. 2011 Jun;127(6):1622-4. doi: 10.1016/j.jaci.2011.04.009.
  37. Werfel T, Allam JP, Biedermann T, Eyerich K, Gilles S, Guttman-Yassky E, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J Allergy Clin Immunol. 2016 Aug;138(2):336-49. doi: 10.1016/j.jaci.2016.06.010.
  38. Radulovic S, Wilson D, Calderon M. Systematic reviews of sublingual immunotherapy (SLIT). Allergy. 2011 Jun;66(6):740-52. doi: 10.1111/j.1398-9995.2011.02583.x.